JPRN-UMIN000001490已完成2 期
Multicenter phase II study of modified FOLFOX6 and bevacizumab in chemonaive advanced or recurrent colorectal cancer. - PROMETEUS I
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patient with contraindication to oxaliplatin, 5-FU, l-LV, or Bevacizumab.
研究者
相似试验
已完成
2 期
Multicenter Phase II study of modified FOLFOX7(combination chemotherapy of infusional 5-FU/l-Leucovorin and intermittent Oxaliplatin)with bevacizumab in the first-line therapy of colorectal cancer - CRAFT trialadvanced colorectal cancerJPRN-UMIN000002354Epidemiological and Clinical Research Information Network (ECRIN)50
已完成
2 期
Randomized phase II study of mFOLFOX6 versus TS-1/CPT-11 in patients with advanced/recurrent colorectal cancerPatients with advanced and/or recurrent colorectal cancerJPRN-UMIN000000786OGSG70
撤回
2 期
Colorectal Cancer RECHALLENGEColorectal NeoplasmsNCT00988897Sanofi
招募中
2 期
Multicenter phase II trial of mFOLFOX6 with cetuximab as active chemotherapy regimen for liver metastases inappropriate for curative resection in EGFR positive and KRAS wild type colorectal cancerEGFR positive and KRAS wild type colorectal cancer with liver metastases inappropriate for curative resectionJPRN-UMIN000004683Tohoku - Six Universities Research Group by Experts (T-SURGE)50
已完成
2 期
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal CancerColon CancerNCT00193219SCRI Development Innovations, LLC36